Interferon alpha 1 Antibody - #DF6086

(7)   (5)  
Product: Interferon alpha 1 Antibody
Catalog: DF6086
Description: Rabbit polyclonal antibody to Interferon alpha 1
Application: WB IHC IF/ICC
Cited expt.: WB
Reactivity: Human, Mouse, Rat
Prediction: Pig
Mol.Wt.: 22kDa; 22kD(Calculated).
Uniprot: P01562
RRID: AB_2838054

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(88%)
Clonality:
Polyclonal
Specificity:
Interferon alpha 1 Antibody detects endogenous levels of total Interferon alpha 1.
RRID:
AB_2838054
Cite Format: Affinity Biosciences Cat# DF6086, RRID:AB_2838054.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

IFL; IFN alpha; IFN alpha 1/13; IFN alpha 1b; IFN alphaD; IFN; IFN-alpha-1/13; IFNA@; IFNA1; IFNA1_HUMAN; IFNA13; Interferon alpha 1; Interferon alpha-1/13; Interferon alpha-D; Interferon alpha1; Interferon, alpha 13; LeIF D;

Immunogens

Immunogen:

A synthesized peptide derived from human Interferon alpha 1, corresponding to a region within the internal amino acids.

Uniprot:

P01562(IFNA1_HUMAN) >>Visit HPA database.

Gene(ID):
IFNA1; IFNA13(3439)
Description:
Interferon-α1 is a member of the Type I IFN (1) family best known for their antiviral activity. Most nucleated cells produce one or more Type I IFNs in response to viral infection (2). Secreted Type I IFN then induces viral protective responses in neighboring non-infected cells. Type I IFNs also enhance virus-induced apoptosis (3). Other IFN-α1 activities include enhancement of dendritic cell maturation and cytotoxic T cell activity (4). IFN-α1 binds to the IFN-αR1 and IFN-αR2 heterodimer (1). Intracellular signaling through the Jak/Stat pathway is best characterized (3). However, the PI3K, ERK, and p38 kinase pathways are also involved (5). The antiviral activities of the IFNs have led to their use in treating viral infections (4). Type I IFNs also appear to have an integral role in several autoimmune diseases (6).
Sequence:
MASPFALLMVLVVLSCKSSCSLGCDLPETHSLDNRRTLMLLAQMSRISPSSCLMDRHDFGFPQEEFDGNQFQKAPAISVLHELIQQIFNLFTTKDSSAAWDEDLLDKFCTELYQQLNDLEACVMQEERVGETPLMNADSILAVKKYFRRITLYLTEKKYSPCAWEVVRAEIMRSLSLSTNLQERLRRKE

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
88
Horse
0
Bovine
0
Sheep
0
Dog
0
Xenopus
0
Zebrafish
0
Chicken
0
Rabbit
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

Research Backgrounds

Function:

Produced by macrophages, IFN-alpha have antiviral activities. Interferon stimulates the production of two enzymes: a protein kinase and an oligoadenylate synthetase.

Subcellular Location:

Secreted.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Family&Domains:

Belongs to the alpha/beta interferon family.

Research Fields

· Cellular Processes > Cell growth and death > Necroptosis.   (View pathway)

· Environmental Information Processing > Signaling molecules and interaction > Cytokine-cytokine receptor interaction.   (View pathway)

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Jak-STAT signaling pathway.   (View pathway)

· Human Diseases > Infectious diseases: Bacterial > Tuberculosis.

· Human Diseases > Infectious diseases: Viral > Hepatitis C.

· Human Diseases > Infectious diseases: Viral > Hepatitis B.

· Human Diseases > Infectious diseases: Viral > Measles.

· Human Diseases > Infectious diseases: Viral > Influenza A.

· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.

· Human Diseases > Infectious diseases: Viral > Herpes simplex infection.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Immune diseases > Autoimmune thyroid disease.

· Organismal Systems > Immune system > Toll-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > NOD-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > RIG-I-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > Cytosolic DNA-sensing pathway.   (View pathway)

· Organismal Systems > Immune system > Natural killer cell mediated cytotoxicity.   (View pathway)

References

1). FAM210B activates STAT1/IRF9/IFIT3 axis by upregulating IFN-α/β expression to impede the progression of lung adenocarcinoma. Cell Death & Disease, 2025 [IF=8.1]
2). FAM210B activates STAT1/IRF9/IFIT3 axis by upregulating IFN-α/β expression to impede the progression of lung adenocarcinoma. Cell death & disease, 2025 (PubMed: 39900908) [IF=8.1]
3). Immunoregulatory programs in anti-N-methyl-D-aspartate receptor encephalitis identified by single-cell multi-omics analysis. Clinical and translational medicine, 2025 (PubMed: 39779473) [IF=7.9]

Application: WB    Species: mice and human    Sample:

FIGURE 5 Dysregulation of myeloid cells in anti-NMDARE. (A) A UMAP plot displaying four myeloid cell subtypes, coloured by annotated clusters. Inset: The proportions of four types of myeloid cells in Ps and HCs. (B) Left: A heatmap showing the expression of DEGs (Likelihood Ratio test, Padj < .01, |log2FC| > .5) in 100 cells sampling from three myeloid cell subtypes, respectively. Each row represents a DEG, and each column represents a sampled cell. The colour indicates the z-transformed gene expression (z-score range is −.5 to .5). Right: Function enrichment results of the upregulated genes in cMs, ncMs and cDCs, respectively. (C) A bubble plot displaying the antigen receptor protein-encoding gene expression levels in four myeloid subtypes. The colour represents the expression ratio, and the size represents the log2FC between Ps and HCs. The border colours of the dots indicate the significance (p-value by Wilcox rank sum test) of the comparison. The red triangle marks the four most significantly different genes. (D) A violin plot depicting the expression levels of four receptor genes in four myeloid subtypes in Ps and HCs (Wilcoxon rank sum test). *p < .05, **p < .01, ***p < .001. (E) A bubble plot depicting the expression levels of TNF pathway ligand–receptor genes in 16 immune cell subtypes. The colour of the bubbles represents the log2 fold-change in expression between Ps and HCs, while the border colour indicates the p-value of the difference (Wilcoxon rank sum test). The size of each bubble corresponds to the percentage of expression. The background shading highlights significant cell–cell interactions by CellChat (p < .01), and the different background frames and central lines represent distinct ligand–receptor pairs. (F) The levels of IFN-α and TNF-α in plasma of HCs (n = 7), acute phase anti-NMDARE (n = 7), convalescence anti-NMDARE (n = 7) and recurrent stage anti-NMDARE (n = 6). Each sample was processed in three technical replicates. The p-values were calculated by the one-way ANOVA method, *p < .05, **p < .01, ***p < .001. (G) The levels of IFN-α in the serum of humanised mice engrafted with PBMCs from anti-NMDARE patients (Patient), healthy donors (HC) and medium-only controls (NC) were assessed using Western blot analysis. Each group comprised three samples. p-Values were calculated using T-test, with significance defined as *p < .05, **p < .01 and ***p < .001.
4). BCG-trained macrophages couple LDLR upregulation to type I IFN responses and antiviral immunity. Cell Reports, 2025 [IF=7.5]
5). Tongmai granules improve rat hippocampal injury by regulating TLR4/MyD88/AP-1 signaling pathway. JOURNAL OF ETHNOPHARMACOLOGY, 2022 (PubMed: 34838942) [IF=4.8]
6). Poly (I: C) exposure during in vitro fertilization disrupts first cleavage of mouse embryos and subsequent blastocyst development. JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2022 (PubMed: 35525084) [IF=2.9]
7). Granulin in renal tubular epithelia is associated with interstitial inflammation and activates the TLR9-IFN-α pathway in lupus nephritis. Lupus, 2024 (PubMed: 38334360) [IF=1.9]

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.